After we set the constraints on the positive number of control subjects to less than 5%, as shown in Figure 2A, there are 52.0% of HCC sera with positive autoantibody reaction to PAX5, which is significantly higher than those of the CH sera (22.2%) and NC (4.7%) groups. This evidence concerns the gene PAX5 and hepatocellular carcinoma.